ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.70
+0.09 (1.05%)
At close: Feb 20, 2026, 4:00 PM EST
8.70
0.00 (-0.02%)
After-hours: Feb 20, 2026, 7:59 PM EST
ImmunityBio Stock Forecast
Stock Price Forecast
The 5 analysts that cover ImmunityBio stock have a consensus rating of "Strong Buy" and an average price target of $11.8, which forecasts a 35.63% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $24.
Price Target: $11.8 (+35.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +175.86% | Feb 19, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +175.86% | Feb 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +14.94% | Jan 26, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +175.86% | Jan 23, 2026 |
| BTIG | BTIG | Strong Buy Maintains $6 → $9 | Strong Buy | Maintains | $6 → $9 | +3.45% | Jan 23, 2026 |
Financial Forecast
Revenue This Year
115.02M
from 14.75M
Increased by 680.06%
Revenue Next Year
218.93M
from 115.02M
Increased by 90.34%
EPS This Year
-0.41
from -0.62
EPS Next Year
-0.29
from -0.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 119.3M | 268.9M | ||||
| Avg | 115.0M | 218.9M | ||||
| Low | 108.7M | 176.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 709.0% | 133.8% | ||||
| Avg | 680.1% | 90.3% | ||||
| Low | 637.1% | 53.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.37 | -0.25 | ||||
| Avg | -0.41 | -0.29 | ||||
| Low | -0.46 | -0.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.